Healthcare provider profile · identity verified

Anh Q. Do, MD

Family Practice · ANAHEIM, CA · NPI 1205984119

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	852	380
Amlodipine Besylate	Amlodipine Besylate	375	190
Lisinopril	Lisinopril	335	157
Losartan Potassium	Losartan Potassium	306	140
Rosuvastatin Calcium	Rosuvastatin Calcium	266	139
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	213	83
Simvastatin	Simvastatin	207	95
Levothyroxine Sodium	Levothyroxine Sodium	189	95
Pantoprazole Sodium	Pantoprazole Sodium	188	91
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	178	82
Metformin Hcl	Metformin Hcl	146	65
Terazosin Hcl	Terazosin Hcl	144	52
Alendronate Sodium	Alendronate Sodium	140	69
Gabapentin	Gabapentin	130	70
Metoprolol Tartrate	Metoprolol Tartrate	129	56
Omeprazole	Omeprazole	125	64
Albuterol Sulfate Hfa	Albuterol Sulfate	123	80
Glipizide	Glipizide	123	64
Metformin Hcl Er	Metformin Hcl	120	61
Atenolol	Atenolol	119	74
Meloxicam	Meloxicam	115	82
Trazodone Hcl	Trazodone Hcl	113	55
Tamsulosin Hcl	Tamsulosin Hcl	93	50
Hydrochlorothiazide	Hydrochlorothiazide	89	54
Pradaxa	Dabigatran Etexilate Mesylate	88	37
Famotidine	Famotidine	85	37
Finasteride	Finasteride	79	31
Allopurinol	Allopurinol	76	36
Prednisone	Prednisone	73	61
Furosemide	Furosemide	67	40
Potassium Chloride	Potassium Chloride	64	36
Fluoxetine Hcl	Fluoxetine Hcl	57	22
Ezetimibe	Ezetimibe	49	23
Azithromycin	Azithromycin	48	48
Escitalopram Oxalate	Escitalopram Oxalate	48	26
Carvedilol	Carvedilol	47	21
Triamcinolone Acetonide	Triamcinolone Acetonide	45	36
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	44	25
Ibuprofen	Ibuprofen	44	32
Ozempic	Semaglutide	43	16
Spiriva Respimat	Tiotropium Bromide	42	15
Buspirone Hcl	Buspirone Hcl	40	19
Ondansetron Odt	Ondansetron	40	28
Alvesco	Ciclesonide	39	26
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	39	19
Tramadol Hcl	Tramadol Hcl	39	32
Donepezil Hcl	Donepezil Hcl	38	19
Cephalexin	Cephalexin	36	34
Clobetasol Propionate	Clobetasol Propionate	36	20
Bisoprolol Fumarate	Bisoprolol Fumarate	35	19
Jardiance	Empagliflozin	34	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	16
Doxycycline Monohydrate	Doxycycline Monohydrate	33	32
Humulin N	Insulin Nph Human Isophane	33	12
Fluticasone Propionate	Fluticasone Propionate	32	16
Hydralazine Hcl	Hydralazine Hcl	32	17
Lactulose	Lactulose	32	19
Morphine Sulfate Er	Morphine Sulfate	31	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	31	11
Sertraline Hcl	Sertraline Hcl	31	20
Alprazolam	Alprazolam	30	15
Amoxicillin	Amoxicillin	29	28
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	29	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	28	28
Bupropion Hcl Sr	Bupropion Hcl	28	12
Liraglutide	Liraglutide	28	suppressed
Warfarin Sodium	Warfarin Sodium	28	15
Acyclovir	Acyclovir	27	21
Wixela Inhub	Fluticasone Propion/Salmeterol	27	19
Clopidogrel	Clopidogrel Bisulfate	26	14
Colchicine	Colchicine	26	16
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	24	24
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	23
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	24	17
Naltrexone Hcl	Naltrexone Hcl	23	suppressed
Nitroglycerin	Nitroglycerin	22	13
Temazepam	Temazepam	22	15
Montelukast Sodium	Montelukast Sodium	21	11
Naproxen	Naproxen	20	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	19	suppressed
Hydrocortisone	Hydrocortisone	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Azelastine Hcl	Azelastine Hcl	18	suppressed
Glipizide Er	Glipizide	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	14
Memantine Hcl	Memantine Hcl	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	16
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Victoza 2-Pak	Liraglutide	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	11
Fenofibrate	Fenofibrate	17	suppressed
Lorazepam	Lorazepam	17	13
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Cartia Xt	Diltiazem Hcl	16	11
Propranolol Hcl	Propranolol Hcl	16	suppressed
Amiodarone Hcl	Amiodarone Hcl	15	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Bupropion Xl	Bupropion Hcl	14	11
Estradiol	Estradiol	14	12
Mometasone Furoate	Mometasone Furoate	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	13
Retin-A	Tretinoin	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Fluocinonide	Fluocinonide	13	12
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	13	13
Mirtazapine	Mirtazapine	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	13
Valacyclovir	Valacyclovir Hcl	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	11
Ampicillin Trihydrate	Ampicillin Trihydrate	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Metronidazole	Metronidazole	12	12
Cefuroxime	Cefuroxime Axetil	11	11
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error